logo-loader
viewValiRx PLC

ValiRx shares jump as firm cleared to increase clinical trial dosing

Investors were also told data from the trial is currently being collated for examination by independent experts, with Dr Mark Linch appointed as principal investigator

researcher using microscope
Thus far, VAL201 has met the goals for this early-phase trial, which is designed to assess whether the compound is safe and well tolerated

ValiRx Plc (LON:VAL) shares jumped higher on Thursday on news the firm has been given regulatory clearance to increase the dose of its VAL201 drug following an amendment to the clinical trial it is currently carrying out.

The first-in-human study of men suffering prostate cancer has revealed the safe toxicological limits are higher than suggested by pre-clinical assessments of the compound.

“The approval given to relax the restrictions previously applied to the trial, mean that a more effective use of VAL201 can be achieved, with respect to concentration and timing and regarding increased flexibility in the administration of the drug,” investors were told.

The changes to dosing strategies, signed off by the Medicines and Healthcare products Regulatory Agency, will allow researchers to develop further clinical trial protocols that are being designed to identify the most effective approach to treating patients.

Thus far, VAL201 has met the goals for this early-phase trial, which is designed to assess whether the compound is safe and well tolerated. The company said results on both scores continued to be “acceptable”.

Moreover, it has seen “further evidence of the compound's positive effect in reducing the progress of prostate cancer”.

The data from the trial is currently being collated for examination by independent experts and results will be available in “due course”, ValiRx said.

The firm’s chief operating officer, George Morris, added: “Now, as the trial is delivering an extensive and positive output, it is also providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which we will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved."

In the same announcement, ValiRx said Dr Mark Linch had been appointed as principal investigator to its clinical trial team at University College London Hospital. 

He is a consultant medical oncologist specialising in the treatment of prostate and bladder cancer.

In opening deals, ValiRx shares were 25% higher at 0.295p.

 -- Adds share price --

Quick facts: ValiRx PLC

Price: 0.105 GBX

AIM:VAL
Market: AIM
Market Cap: £1.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read